Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 1989 • ACR Convergence 2024
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Minerva Nong¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh³ and Anne Bass⁴, ¹Hospital for Special Surgery, Tampa, FL, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
Abstract Number: 0344 • ACR Convergence 2024
Characteristics of Patients with Antisynthetase Antibodies
Danny Kasto¹, Michael McLucas², Anne-Marie Aubin², Armando Faigl² and Gabor Major¹, ¹Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, New South Wales, Australia, ²Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, Australia
Background/Purpose: Aminoacyl transfer RNA synthetase antibodies (ASAbs) are associated with a range of clinical manifestations, including severe lung and muscle disease and are postulated to…
Abstract Number: 1994 • ACR Convergence 2024
Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study
Javier Narvaez-García¹, Arturo Llobell², Andrés Ponce³, Antonio Gomez-Centeno⁴, Ana Milena Millán⁵, Hèctor Corominas⁵, Joan Miquel Nolla¹ and Jose Alfredo Gomez-Puerta⁶, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario Parc Taulí, Sabadell, Spain, ³Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Hospital Quiron Barcelona, Barcelona, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: To analyse the clinical presentation, treatment response, and outcomes of arthritis induced by immune checkpoint inhibitors (ICIs) in patients with cancer.Methods: Retrospective observational study conducted…
Abstract Number: 0444 • ACR Convergence 2024
Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
Philip Carlucci¹, Robert Clancy², Mala Masson³, Colin Phoon⁴, Ashley Roman⁴, Peter Izmirly⁵, Amit Saxena⁶, H Michael Belmont⁴, Christina Penfield⁴, Young Mi Lee⁴, Julie Nusbaum⁷, Andrew Rubenstein⁴, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad⁹, Karla Bermudez-Wagner⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Whitnee Hogan¹², Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Jaclyn Phillips¹⁷, Stephanie Levasseur¹⁸, Miwa Geiger¹⁹, Erin Paul²⁰, Sonal Owens²¹, Kristopher Cumbermack²², Jyothi Matta²³, Gary Joffe²⁴, Christopher Lindblade²⁵, Carl Weiner²⁶, Caitlin Haxel²⁷, Katherine Kohari²⁸, Joshua Copel²⁸, James Strainic²⁹, Tam Doan³⁰, Shreya Sheth³⁰, Stacy Killen³¹, Theresa Tacy³², Michelle Kaplinski³², Nicola Fraser⁴, Kelly Ruggles³³, Bettina Cuneo³⁴ and Jill Buyon³⁵, ¹New York University School of Medicine, New York, NY, ²Columbia University Medical Center, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹Eastern Virginia Medical School, Norfolk, VA, ¹⁰Atrium Health Levine Children's Hospital, Charlotte, NC, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, UT, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai School of Medicine, New York, NY, ²⁰Atlantic Health System, Morristown, NJ, ²¹University of Michigan, Ann Arbor, MI, ²²University of Kentucky, Lexington, KY, ²³University of Louisville, Louisville, KY, ²⁴Perinatal Associates of New Mexico, Albuquerque, NM, ²⁵Phoenix Children's Hospital, Phoenix, AZ, ²⁶Dignity Health, Phoenix, AZ, ²⁷University of Vermont Children's Hospital, Burlington, VT, ²⁸Yale University, New Haven, CT, ²⁹UH Rainbow Babies, Cleveland, OH, ³⁰Baylor College of Medicine, Houston, TX, ³¹Vanderbilt University, Nashville, TN, ³²Stanford University, Stanford, CA, ³³NYU Grossman School of Medicine, Brooklyn, NY, ³⁴University of Arizona College of Medicine, Tucson, AZ, ³⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…
Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0619 • ACR Convergence 2024
Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, BETTINA ESCOLANO², ENOCH J ABBEY² and Amanda Sammut³, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ³New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
Abstract Number: 2040 • ACR Convergence 2024
Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice
Martin Michaud¹, Laurent Sailler², Mélanie LEMEU³, Brice CASTEL⁴, Fabienne Vacheret⁵, Laurent Prudhomme⁶ and Grégory Pugnet⁷, ¹Clinique Saint Exupery, Toulouse, France, ²CHU Toulouse, Toulouse, France, ³CH Albi, Albi, France, ⁴CH TARBES, Tarbes, France, ⁵CH Perpignan, Perpignan, France, ⁶CH Castres, Castres, France, ⁷Toulouse Rangueil University Hospital, Toulouse, France
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory syndrome marked by recurrent pericardial inflammation after an initial episode of acute pericarditis. Standard treatment involves…
Abstract Number: 0855 • ACR Convergence 2024
Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study
Alexandra Kachaner¹, Arthur Mageau¹, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled…
Abstract Number: 2043 • ACR Convergence 2024
Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study
Fatma Zehra Avci¹, Feyza Nur Azman², Elif Sila Unsal³ and Serdal Ugurlu⁴, ¹Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, ⁴Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) typically begins in childhood. It has been demonstrated that colchicine can reduce FMF attacks, prevent the development of amyloidosis, and…
Abstract Number: 0856 • ACR Convergence 2024
Comparative Effectiveness of Disease Modifying Antirheumatic Drugs for Cardiac Sarcoidosis
Michael Putman¹, Lisbeth Brooks², William Kivlin², Divyanshu Mohananey² and Viktoriya Sabchyshyn², ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: No studies to date have evaluated the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for cardiac sarcoidosis. Methods: We performed a retrospective cohort…
Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Dongze Wu¹ and Yingzhao jin², ¹Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), ²Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
Abstract Number: 0857 • ACR Convergence 2024
Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…
Abstract Number: 2054 • ACR Convergence 2024
Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Paula García Escudero¹, Marta López I Gómez², Berta Magallanes López³, Diego Dios Santos⁴, Francisco Javier Toyos Sáenz de Miera⁵, Alicia García Dorta⁶, José Ángel Hernández Beriain⁷, Íñigo Rúa-Figueroa⁸, cristiana sieiro santos⁹, Elvira Díez Álvarez¹⁰, Marta Ibáñez Martínez¹¹, Beatriz Frade-Sosa¹², Judit Font Urgelles¹³, Meritxell Sallés Lizarzaburu¹⁴, Elena Riera Alonso¹⁵, Ernesto Trallero Araguás¹⁶, Eugenia Enríquez Merayo¹⁷, Maria Rodriguez-Laguna¹⁸, irene monjo¹⁹, Carolina Merino²⁰, Paloma Vela-Casasempere²¹, Ignacio Vázquez Gómez²², Jose Alberto Miranda Filloy²³, Rafael Benito Melero-Gonzalez²⁴, Clara Garcia Belando²⁵, Giuliano Boselli²⁶, Alina Lucica Boteanu²⁷, Dolly Viviana Fiallo Suárez²⁸, Cristina Corrales Selaya²⁹, ALBERTO MARIANO RUIZ ROMAN³⁰ and Jaime Calvo-Alén³¹, ¹Hospital Universitario Araba, Vitoria, ²Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ⁴C. H. U. A Coruña, C. H. U. A Coruña, ⁵H. U. Virgen Macarena, H. U. Virgen Macarena, ⁶Rheumatologist, La Laguna, Spain, ⁷Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ⁸Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁰Complejo Asistencial Universitario de León, León, Spain, ¹¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clinic de Barcelona, Barcelona, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ¹⁵Mutua de Terrasa, Barcelona, ¹⁶Hospital Vall D'Hebron, Barcelona, Spain, ¹⁷Hospital 12 de Octubre, Madrid, ¹⁸Resident in Rheumatology, Madrid, Spain, ¹⁹University Hospital La Paz, Madrid, Spain, ²⁰Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²¹Hospital General Universitario Alicante, Alicante, Spain, ²²H. U. Dr. Peset, Valencia, ²³C. H. U. Lucus Augusti, Lugo, Spain, ²⁴CHU Ourense, O Carballino, Spain, ²⁵H. C. U. Virgen de la Arrixaca, Murcia, ²⁶hospital miguel servet, zaragoza, Aragon, Spain, ²⁷H.U. Ramón y Cajal, Madrid, Spain, ²⁸H. U. de Gran Canaria. Dr. Negrin, H. U. de Gran Canaria, ²⁹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ³⁰Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, ³¹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is an autoinflammatory disorder caused by a mutation in the UBA1 gene, which leads to a heterogeneous clinical presentation and progressive bone…
Abstract Number: 0877 • ACR Convergence 2024
Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors
Shailly Mehrotra¹, Yasuyo Sano¹, Elizabeth Wilson¹, Chandrasekar Durairaj², Kok-Fai Kong¹, Guliang Xia³, Faith Dunbar³, Taylor Spector¹, Christopher Bunick⁴ and Iain McInnes⁵, ¹Takeda Development Center Americas, Inc., Cambridge, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, ⁴Yale University School of Medicine, New Haven, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom
Background/Purpose: Zasocitinib (TAK-279), an oral, allosteric, selective, tyrosine kinase 2 (TYK2) inhibitor in late-stage clinical development for the treatment of immune-mediated inflammatory diseases including psoriatic…
Abstract Number: 2660 • ACR Convergence 2024
Developing Predictive Models for the Diagnosis of VEXAS Syndrome
Daniel Montes¹, Andrew C. Hanson², Hannah Langenfeld¹, Cynthia Crowson¹, Mrinal Patnaik¹, Ronald Go¹, Alexander Hines¹, Kambiz Kalantari¹, Yael Kusne³, Terra Lasho², Abhishek Mangaonkar¹, Horatiu Olteanu¹, Kaaren Reichard¹, Megan Sullivan⁴, David Viswanatha¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Phoenix, AZ, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently identified autoinflammatory disorder with a heterogenous presentation. Patients may experience delays in diagnosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].